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Abstract: Granulosa cell tumors are rare ovarian tumors that can arise during pregnancy. We present
a new case of recurrent adult granulosa cell tumor (AGCT) in pregnancy and a systematic review
of the literature. The new case described is a 41-year-old woman G5P1122 with a prior history
of AGCT that was referred to our center at 29 weeks because of a symptomatic abdominal mass,
compatible with a possible recurrence of AGCT. At 36 + 3 weeks, she underwent a cesarean delivery
for preterm labor and a total hysterectomy with a radical surgical staging. A healthy female infant
was delivered. The patient received a platinum-based chemotherapy, with a 26-month follow-up
negative for recurrence. Analyzing our case with the four identified by the literature review, three
were recurrent and two were primary AGCT. Only one required surgery for AGCT at 15 weeks, while
another underwent chemotherapy in pregnancy. In the other three cases, surgery for AGCT was
done at the time of cesarean delivery. There were three cases of preterm delivery. All five pregnancies
resulted in the birth of live babies with weight adequate for gestational age. In conclusion, AGCT
diagnosed in pregnancy is rare, reported in only five cases. All gave birth to live babies in the third
trimester, and maternal outcome at up to 18 months showed no recurrence.
Keywords: granulosa cell tumor; pregnancy; recurrence; ovarian cancer; maternal outcome; fetal
outcome; gynecology
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1. Introduction
Granulosa cell tumors account for 5–8% of all ovarian tumors [1]. They are classified
according to histological and clinical presentation in two different types: Adult type
and Juvenile type. The most common is the Adult type, which accounts for 95 % of all
granulosa cell tumors, and it is usually diagnosed in the peri- and post-menopausal period.
Menstrual irregularities, amenorrhea, and endometrial hyperplasia are common symptoms
of Adult granulosa cell tumor (AGCT) [1]. The Juvenile type instead accounts for 5% of
all granulosa cell tumors and is diagnosed in the first two decades of life. Granulosa cell
tumors can also present during pregnancy, although this happens infrequently, in only 10%
of cases [2]. The presentation of AGCT in childbearing age is unusual. We describe a new
case of recurrent AGCT in pregnancy. In addition, we conducted a systematic review of
the literature for primary or recurrent AGCT in pregnancy.

4.0/).
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2. Materials and Methods
Data sources: a review of electronic databases (i.e., MEDLINE, Scopus, ClinicalTrials.
gov, accessed on 20 October 2021, EMBASE, Science Direct, the Cochrane Library at
CENTRAL Register of control trials, Scielo) was conducted from their inception until July
2021. Cases or case series of pregnant women with a history of AGCT diagnosed during
pregnancy were identified by a review of the literature. A new case from our center was
also identified. There were no restrictions of language and geographic location; articles in
foreign languages were adequately translated by the authors. Demographic characteristics,
details of the history of granulosa cell tumor, treatment and management, pregnancy and
neonatology outcomes were reviewed in detail.
Search strategy and study selection: We followed the MOOSE guidelines to review
the literature. The search terms used were “granulosa cell tumor” and “pregnancy”.
Each article was assessed by three investigators S.G., V.B., and A.F.C. No contact with
authors was necessary.
Inclusion criteria: The articles were included if the granulosa cell tumor was of the
Adult type and if it was diagnosed or recurred during pregnancy.
Exclusion criteria: Articles on Juvenile granulosa cell tumor and articles not specifying the type of granulosa cell tumor were excluded. Tumors that were diagnosed after
pregnancy were also excluded. Articles with multiple cases that had the variables analyzed
as a group and did not give separate data for granulosa cell tumor type were excluded.
Case reports of non-malignant lesions were excluded.
3. Results
Case report: A 41-year-old woman G5P1122 was referred to our center in April 2019
at 29 weeks of gestation because of a large symptomatic abdominal mass. The patient
first identified a large bulging on the anterior abdomen in the supraumbilical region,
which was later confirmed by her gynecologist. The ultrasound scan at the referring
hospital showed a 9 cm mass, with hypo- and hyperechoic areas. Regarding her obstetrical
history, the patient reported two spontaneous abortions, respectively in 2000 and 2011, an
uncomplicated pregnancy and cesarean delivery at term in 2012, and a vaginal delivery at
26 weeks of gestation in 2018. During the current index pregnancy, no other maternal or
fetal complications were diagnosed.
She had a history of AGCT, diagnosed in February 2011 with laparoscopic enucleation
of a right ovarian cyst with intraoperative spillage. After histological evaluation, the
definite diagnosis was AGCT. Both the mitotic index and the Ki67 proliferation index
were low: two mitoses per 10 high power field (HPF) and 2%, respectively. Laparoscopic
restaging three months later involved right salpingo-oophorectomy, lymph nodes sampling,
and omental and peritoneal biopsies, which were all negative. Her AGCT was therefore
FIGO stage Ic. No adjuvant treatment was prescribed, and the woman underwent regular
oncological follow-up with negative results. Due to lack of recurrence, she was counseled
that another pregnancy was not contraindicated.
Work-up of her mass during the index pregnancy at 29 weeks included magnetic
resonance imaging (MRI) of the abdomen and pelvis, which revealed an anterior swelling
of the uterine fundus measuring 9.6 × 6.7 × 12 cm3 extending cranio-caudally, with a
partially hematic liquid content (Figure 1). Given the usual slow progression of AGCT
and its prognosis, she was closely followed with ultrasonography at 2–3 weeks intervals.
No changes were detected in morphology and dimensions of the mass, with no new
findings.
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Due to uterine contractions, repeat cesarean delivery originally planned for 37 weeks
Due to uterine contractions, repeat cesarean delivery originally planned for 37 weeks
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four cases
excluded
(Figure
3). with details available on symptoms, three had abdominal symptoms,
while one was asymptomatic. Radiologic work-up for the abdominal symptoms always included an US, and sometimes also an MRI, in the second or early third trimester. Two cases
were instead detected at cesarean delivery, at 32 weeks and at term. Tumor was localized in
one of the ovaries in four out of five cases, and in the remaining case (ours), in the fundus
of the uterus. Tumor dimensions were reported either by radiologic work-up or in surgery
(Table 2).
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Table 1. Patient characteristics and adult granulosa cell tumor history.

First Author

Year

Patient
Age

Gravidity
and Parity

Primary/Recurrent

Guidi

2019

41

G5P1122

Recurrent

Previous Oncological Surgeries before
Pregnancy
Laparoscopic enucleation of an ovarian
cyst on the right ovary initially, then right
salpingo-oophorectomy, lymph nodes
sampling, and omental and peritoneal
biopsies
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Table 1. Patient characteristics and adult granulosa cell tumor history.
First Author

Year

Patient
Age

Gravidity and
Parity

Primary/Recurrent

Previous Oncological Surgeries before
Pregnancy

Guidi

2019

41

G5P1122

Recurrent

Laparoscopic enucleation of an ovarian
cyst on the right ovary initially, then right
salpingo-oophorectomy, lymph nodes
sampling, and omental and peritoneal
biopsies

Aymen

2016

30

G1P0

Primary

NS

Roy

2014

23

G1P0

Primary

NS

Agarwal

2011

26

G1P0

Recurrent

Right salpingo-oophorectomy

Fernandez-cid

2011

35

NS

Primary

NS

NS, not stated.

Table 2. Adult granulosa cell tumor symptoms, work-up and specifics in pregnancy.

First Author

Symptoms/Signs in
the Index Pregnancy
Which Prompted
Work-Up

Week at Radiologic
Work-Up or
Intraoperative
Diagnosis

Radiologic
Work Up

Tumor
Localization

Tumor
Dimension

Guidi

Bulging of a
symptomatic
abdominal mass, that
was palpable and
visible

29

US and MRI

Uterine fundus

9.6 × 6.7 ×
12 cm3 (MRI)

Aymen

Intermittent
abdominal unspecific
pain

32 (CD)

NS

Right ovary

40 × 30 cm (intraoperative)

Roy

NS

At term (CD)

NS

Right ovary

10 × 10 × 5 cm
(intraoperative)

Agarwal

Acute pain and
progressive abdominal
distension

20

US and MRI

Left ovary

9.7 × 7.7 cm
(US-MRI)

Fernandez-cid

Asymptomatic; tumor
detected at routine
abdominal ultrasound

NS

US

Left ovary

17 × 14.1 ×
11.8 cm (US)

CD, tumor detected at cesarean delivery. NS, not stated.

Surgery during pregnancy was done in only one case, a laparoscopic left adnexectomy
at 15 weeks [5]. In three other cases, surgery was done at the time of cesarean delivery, in
the third trimester. These four cases did not have chemotherapy in pregnancy, while the
fifth case [6] was given chemotherapy in pregnancy and also postpartum, and had surgery
only 8 months postpartum (Table 3).
In terms of obstetrical outcome, three cases were delivered at term or near term [5,7],
while two required delivery at 30 weeks for preterm labor [6] and 32 weeks for placental
abruption [8]. The five live babies were of birthweight adequate for gestational age in the
four that reported birthweight (Table 4).
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Table 3. Tumor management during pregnancy.

First Author

Week at
Surgery

Surgery in
Pregnancy

Surgery at Delivery

Intraoperative
Findings and Sites
Positive for AGCT

Chemotherapy
during Pregnancy

Left ovary, bilaterally
in uterosacral
ligaments,
vesico-uterine fold and
douglas pouch.

No

Guidi

36 + 3

No

Total hysterectomy, left
salpingo-oophorectomy,
excision of every
macroscopically visible
nodules in the peritoneum,
and infracolic
omentectomy

Aymen

32

No

Right adnexectomy and
partial omental removing

Omentum

No

Roy

At term

No

Right sided ovariectomy

NS

NS

Adriamycin–
Vincristine (week
21)

NS

Agarwal

Not
applicable

No

No

Significant ascites,
peritoneal implants,
omental thickening,
enlarged paraaortic
lymph nodes and
bilateral pleural
effusion.

Fernandez-cid

15

Laparoscopic left
adnexectomy

No

NS

NS not stated.

Table 4. Obstetrical outcomes.
Gestational Age
Delivery (Weeks
+ Days)

Mode of
Delivery

Pregnancy
Outcome

Birth
Weight
(Grams)

Apgars at 1
and 5 min

36 + 3

Planned
cesarean done
early for
preterm labor

Live birth,
female

2750

9/9

32

Emergency
cesarean for
placental
abruption

Live birth

1925

2/5 *

Roy

At term

Emergency
cesarean for
labor
obstruction

Live birth,
male

2500

NS

Agarwal

30

Vaginal after
preterm labor

Live birth,
male

1200

NS

Fernandezcid

39

Planned
cesarean

Live birth,
female

NS

NS

First Author

Guidi

Aymen

* 10 at 10 min, NS not stated.

Of the four cases that had surgery in pregnancy or at delivery but no chemotherapy, only one required postpartum surgery [8]; three also had chemotherapy (always
including cisplatinum or carboplatinum), while in one postpartum, chemotherapy was not
described (Table 5). Unfortunately, only short-term follow-up of the maternal AGCT, up to
18 months, was available in four cases. The postpartum follow-up showed no recurrence
in all four cases.
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Table 5. Post-delivery tumor management and outcome.
First Author

Surgery after Pregnancy

Chemotherapy after
Pregnancy

Maternal Oncologic
Outcome

Guidi

No

Six cycles of Carboplatin

Follow-up at 26 months
negative for recurrence

Aymen

Total hysterectomy, left
adnexectomy, total
omentectomy, appendicectomy,
and multiple peritoneal biopsies

Four cycles of BEP protocol
(after surgery in pregnancy)

Follow-up at 18-months
negative for recurrence

Roy

NS

Yes (type not described)

NS

Agarwal

Total abdominal hysterectomy
and left salpingo-oophorectomy
(After the chemotherapy and 8
months postpartum)

Six cycles of cisplatin regimen

Follow-up at 10 months after
delivery negative for
recurrence

Fernandez-cid

No

NS

Asymptomatic and at last US
no recurrences

BEP, bleomycin, etoposide, and cisplatinum; CT, chemotherapy, NS, not stated.

4. Discussion
Our review of the literature revealed that AGCT diagnosed as either primary or recurrent tumor in pregnancy is rare, reported in only five cases. Surgery and chemotherapy
during pregnancy was needed in only one case, while the other three had surgery at cesarean delivery. All gave birth to live babies in the third trimester, and maternal outcome at
up to 18 months showed no recurrence. Several other cases of AGCT in pregnancy reported
in the literature do not specify or distinguish type of granulosa cell tumor (Figure 3).
Granulosa cell tumors usually manifest as large unilateral masses with nonspecific
symptoms and specific diagnostic criteria. The recommended management is surgical, also
necessary for tumor staging [1]. These tumors are characterized by a late recurrence, so
long follow-up is advised. If surgical removal of only one ovary is necessary, women with
a history of AGCT can have a spontaneous pregnancy.
The strength of our study is that to our knowledge there are no other reviews of
AGCT occurring as primary or recurrent tumor during pregnancy. Non-English language
studies were not excluded. Limitations were inherent to the details provided by the reports
identified, many reports did not specify or distinguish the type of GCT. The cases included
not always provided all details, and postpartum follow-up was short, at maximum only
18 months.
5. Conclusions
As AGCT is often initially managed with unilateral oophorectomy in women of reproductive age, pregnancy in women with this history is possible. AGCT in pregnancy has
been reported in detail only in five cases. Surgery and chemotherapy are seldom necessary
during pregnancy, as this is usually a slow growing tumor. Short-term maternal and
perinatal outcomes are in general favorable, with surgery for AGCT often done at cesarean,
live births, and postpartum platinum chemotherapy. Care with a multidisciplinary team
including gynecologic oncology surgeons, radiologists, obstetricians and maternal-fetal
specialists, pathologists, anesthesiologists and neonatologists is recommended. Given the
presence of only five total cases of AGCT in pregnancy in the literature, more research is
needed.
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